A startup called Strata Oncology says it plans to give away advanced genetic tests to 100,000 patients struggling with cancer. But there's a profit motive: it hopes to identify patients with specific rare DNA errors and steer them to drug companies.
Strata, which was founded last year and has raised $12 million from investors, says it is set up to run 50,000 next-generation sequencing tests a year. Such tests probe the DNA of tumor tissue, searching for mutations in hundreds of genes at once, hoping to surface clues about what drug a patient should be taking.
A federal safety board next week will consider the first human use of the gene-editing technology CRISPR, according to the National Institutes of Health.
The proposed treatment is an immune therapy in which a patient’s own blood cells will be removed and genetically altered using the technology, a type of molecular scissors able to precisely cut DNA.
The cancer treatment, in development by the University of Pennsylvania, is designed to target myeloma, melanoma, and sarcomas, according to the NIH.
Ni las más de 400 empresas y 731 puestos de trabajo creados, ni las 2.000 solicitudes atendidas. No. Es sobre todo no dejar que ninguna idea viable se quede en una idea, que el trabajo en red sea nuestro motor y, sobre todo, que el factor humano sea la clave de nuestro empeño. No son números, son ilusiones que se hacen realidad lo que hoy compartimos con vosotros.
El año pasado, los ejecutivos de Procter & Gamble Co. se alarmaron al enterarse que Wal-Mart Stores Inc. había colocado los productos de un competidor europeo al lado de Tide (Ace en algunos países), el icónico detergente de la compañía. Fue una bofetada para el gigante de productos de consumo, que durante mucho tiempo ha considerado las estanterías de Wal-Mart como el punto de venta más valioso de sus productos.
A new survey has found that depression among Greeks has dramatically increased, with women being most severely affected.
Greece’s Statistical Authority survey on health is carried out every four years. The first one was conducted in 2009.
After six years of recession, Greece’s public healthcare system has been under enormous pressure due to austerity policies.
12.9% of Greece’s population stressed that it did not receive at all, or received delayed medical care due to a long waiting list, remoteness or problems in transportation (5%), and 9.4% due to lack of doctors and health specialties.
La Universidad Internacional de La Rioja (UNIR) y el centro de estudios MondragonLingua han firmado un acuerdo de colaboración por el que alumnos y exalumnos de la Universidad podrán aprender euskera, y obtener el perfil 3 de HABE, en condiciones económicas especiales.
En las Ofertas Públicas de Empleo para los cuerpos docentes que se convocan en el País Vasco, es necesario acreditar un perfil 3 de competencia lingüística en euskera según el Departamento de Educación del Gobierno Vasco. El perfil 3 corresponde a un nivel C1 del Marco Común europeo.
ULMAko ekipo teknikoak garatutako KOMPAQDRAIN® kanal trinko berria, Max Flow® sistemarekin, Municheko IFAT azokan aurkeztu da, ikusmin handia eraginez.
EROSKI avanza en su apuesta por la multicanalidad con la extensión del servicio de compra online y la ampliación de los puntos de recogida en tienda de dichos pedidos. “Apostamos por la convergencia entre el negocio tradicional y el digital para ofrecer al consumidor, que quiere moverse indistintamente en el mundo on y off line, una experiencia de compra sin fisuras, adaptada a sus necesidades”, ha señalado la directora de comercio electrónico de EROSKI, Mari Mar Escrig.
Private companies in the mobile industry have seen tremendous 661% growth in funding over the past 5 years.
What are the specific industry categories that have been most targeted by investments, and where are deals more thin on the ground?
Using CB Insights data, we drilled into deals to private mobile companies broken down by our subindustry classifications to highlight more saturated areas vs. growth opportunities within mobile. The resulting heat map shows deal activity by CB Insights’ subindustry classifications.
The world’s largest DNA sequencing company says it will form a new company to develop blood tests that cost $1,000 or less and can detect many types of cancer before symptoms arise.
Illumina, based in San Diego, said its blood tests should reach the market by 2019, and would be offered through doctors’ offices or possibly a network of testing centers.
The spin-off’s name, Grail, reflects surging expectations around new types of DNA tests that might do more to defeat cancer than the more than $90 billion spent each year by doctors and hospitals on cancer drugs. Illumina CEO Jay Flatley says he hopes the tests could be a “turning point in the war on cancer.”
